Donor-Derived Disseminated Toxoplasmosis After Liver Transplant (ACG 2026) - Aug 29, 2026 - Abstract #P6426; Pres time: Oct 13, 2026; 10:30 AM - 04:00 PM; Location: Exhibit Halls A - D (Level 3); "He was empirically treated with meropenem and micafungin...Atovaquone should be considered as a second line option for patients at risk of toxoplasmosis who cannot tolerate TMP-SMX due to its activity against both Toxoplasma and Pneumocystis . Figure: Table 1: Infection status of donor and recipient prior to transplant. Figure: Table 2: Results of initial infectious laboratory workup."
Cholestasis • Fibrosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Nephrology • Renal Disease • Septic Shock • Transplantation
|
|
Robert Krahmer MD 1; Ariana Peguero MSN APRN AGACNP 2; Vanessa Arroyo MSN APRN AGACNP-BC 2; Jamie Jeffords MSN APRN 2; Vy Pham MSN APRN AGACNP 2; Abigail Tayamen ACNPC-AG 2; Eduardo Rodriguez Zarate MD FACG 2
|